Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP977924.RAD-Qs5w60v4c2gK7Qq4R0CVnXDJYxl0mbgpvkAJ1oTgQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP977924.RAD-Qs5w60v4c2gK7Qq4R0CVnXDJYxl0mbgpvkAJ1oTgQ130_assertion type Assertion NP977924.RAD-Qs5w60v4c2gK7Qq4R0CVnXDJYxl0mbgpvkAJ1oTgQ130_head.
- NP977924.RAD-Qs5w60v4c2gK7Qq4R0CVnXDJYxl0mbgpvkAJ1oTgQ130_assertion description "[Treatment duration in patients with chronic hepatitis C in the era of standard interferon-alpha plus ribavirin was tailored according to hepatitis C virus (HCV) genotype: patients infected with HCV-1 were treated for 48 weeks, patients infected with HCV-2/3 for 24 weeks.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP977924.RAD-Qs5w60v4c2gK7Qq4R0CVnXDJYxl0mbgpvkAJ1oTgQ130_provenance.
- NP977924.RAD-Qs5w60v4c2gK7Qq4R0CVnXDJYxl0mbgpvkAJ1oTgQ130_assertion evidence source_evidence_literature NP977924.RAD-Qs5w60v4c2gK7Qq4R0CVnXDJYxl0mbgpvkAJ1oTgQ130_provenance.
- NP977924.RAD-Qs5w60v4c2gK7Qq4R0CVnXDJYxl0mbgpvkAJ1oTgQ130_assertion SIO_000772 15158341 NP977924.RAD-Qs5w60v4c2gK7Qq4R0CVnXDJYxl0mbgpvkAJ1oTgQ130_provenance.
- NP977924.RAD-Qs5w60v4c2gK7Qq4R0CVnXDJYxl0mbgpvkAJ1oTgQ130_assertion wasDerivedFrom befree-20150227 NP977924.RAD-Qs5w60v4c2gK7Qq4R0CVnXDJYxl0mbgpvkAJ1oTgQ130_provenance.
- NP977924.RAD-Qs5w60v4c2gK7Qq4R0CVnXDJYxl0mbgpvkAJ1oTgQ130_assertion wasGeneratedBy ECO_0000203 NP977924.RAD-Qs5w60v4c2gK7Qq4R0CVnXDJYxl0mbgpvkAJ1oTgQ130_provenance.